Global Montelukast API Market Research Report Forecast to 2023
|発行||Market Research Future||商品コード||908213|
|出版日||ページ情報||英文 94 Pages
|モンテルカストAPIの世界市場：2023年までの予測 Global Montelukast API Market Research Report Forecast to 2023|
|出版日: 2019年07月31日||ページ情報: 英文 94 Pages||
Montelukast API Market Research Report - Global Forecast till 2023
An orally offered leukotriene receptor antagonist that used widely for the treatment of asthma is Montelukast API. Respiratory problems related with the exercise-induced bronchospasm is prevented by the same. Also, the symptoms of hay fever and allergic rhinitis is relieved through this. The leukotrienes that are responsible for causing or worsening asthma and related allergies is blocked by this drug that works by reducing the inflammation in the airways.
The growing incidence of asthma is expected to lead the market graph. However, the availability of alternatives and unfavorable effects connected with montelukast are likely to detain the market graph.
The Global Montelukast API Market is anticipated to list a CAGR of 3.38% to reach USD 1,430,215.2 thousand by 2023. It is high in demand globally for asthma treatment. The growing rate of allergic rhinitis cases is boosting the growth of the segment expected to display the highest CAGR of 3.11% from 2018 to 2023.
North America considered for the largest market share of 39.25% in 2017, and the regional market is expected to list a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the rapid CAGR. The China market is anticipated to list the maximum growth rate of 5.10% during the forecast period from 2018 to 2023. The Europe market is predictable to surpass USD 396,258 thousand by 2023. Growing incidence of asthma, COPD, and allergies are striving to the growth of the Montelukast API market in the region. The key contributor to the growth of the regional market is UK which is followed by France. Montelukast API Manufacturers, Pharmaceutical Companies, Contract Research Organizations, Contract Manufacturing Organizations are projected spectators.
The Global Montelukast API Market is segmented in two parts, by Application and by region. By Application it's sub-divided into Asthma, Allergic Rhinitis, Bronchospasm, Urticaria and Others. By Region it is divided into six countries i.e.; North America covering 2 countries US and Canada, Latin America, Europe while also covering Germany, Italy, Eastern Europe, Spain, UK, the Rest of Europe, Asia-Pacific covering countries like India, China, Japan, Rest of Asia-Pacific, Middle East and Africa.
Geographically, the Global Montelukast API Market is intersected into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Some major players in Montelukast API Market are: Sandoz International GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Dr. Reddy's Laboratories Ltd (India), Morepen Laboratories Ltd (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (Israel), Vintage Pharmaceuticals Inc (US), Hikma Pharmaceuticals PLC (UK), Glenmark (India), Merck Sharp & Dohme Corp (US), Sandoz International GmbH (Germany), Hetero (India) and Aurobindo Pharma (India).